A University of Cincinnati and UC Davis team reported proof of concept for an AAV gene therapy aimed at hydrocephalus at its source. In animal models, the therapy targeting cerebrospinal-fluid-producing cells reduced hydrocephalus-related brain swelling, positioning the approach as a potential minimally invasive alternative to shunt surgery. The work emphasizes the delivery to CSF-producing cell populations rather than downstream effects of pressure and fluid accumulation. For gene therapy developers, the finding strengthens a tractable target-location strategy for neurological indications where repeated interventions remain common and invasive.